Better High-Yield Dividend Stock: Pfizer vs. Kimberly-Clark

Michael Douglass • 6 minute read
Reviewed by: Michael Douglass
Last updated Nov 13, 2026

Pressmaster from Pressmaster and Ri_Ya from pixabay

Key Takeaways

  • Kimberly-Clark closed its Kenvue acquisition on Nov. 2, and Pfizer raised its 2026 revenue guidance by $1.5 billion at the midpoint a day later.
  • Pfizer yields 6% and Kimberly-Clark 4.6%, and each dividend used up close to 90% of free cash flow over its latest reported twelve months.
  • Kimberly-Clark’s 281.1 million new shares add about $1.44 billion a year to its dividend bill, and analysts expect Pfizer’s normalized EPS to fall to $2.45 in 2028.
  • Pfizer trades at 10x forward earnings, against 16x for Kimberly-Clark.

Kimberly-Clark (KMB) closed its acquisition of Kenvue on Nov. 2. The next day, Pfizer (PFE) raised its 2026 revenue guidance by $1.5 billion at the midpoint, to a range of $62.0 billion to $64.0 billion.

Both pieces of news bear on the cash behind a big dividend. So which is the better high-yield stock?

MetricPfizer (PFE)Kimberly-Clark (KMB)
Dividend yield6.0%4.6%
Dividend growth, fiscal 2020-20252.5% a year3.3% a year
Dividend record (company’s own count)352 straight quarterly dividends54 straight years of raises
Cash dividend payout ratio (TTM)89% (to June 28, 2026)87% (to Sept. 30, 2026)
Net debt/EBITDA (LTM)1.9x1.2x
Interest coverage (LTM)7.0x13.1x

Source: TIKR, Nov. 9, 2026; dividend records from each company.

6 safe dividend stocks paying retirees 6%+ yields

There are over 100 stocks paying 6%+ annual dividends today.

But after an extensive investment review leveraging TIKR’s proprietary data, we now believe only six of them are truly safe for retirees.

They’re all yours for free as part of our new investment report, which you can access right here.

Pfizer’s new drugs are doing more of the work

Pfizer’s third-quarter revenue was $16.6 billion, relatively flat operationally from a year earlier. Launched and acquired products grew 32% operationally, which made up for Paxlovid falling 63%.

The cash behind the dividend has been bumpier. Free cash flow fell from $29.9 billion in fiscal 2021 to $9.08 billion in fiscal 2025, and it came up short of the dividend in both fiscal 2023 and fiscal 2025:

Bar chart from TIKR of Pfizer's free cash flow vs. common dividends paid, $ billions, fiscal 2016–2025.
Pfizer (PFE): free cash flow vs. common dividends paid, $ billions, fiscal 2016–2025 (TIKR)

The twelve months to June 28, 2026, look better: $10.98 billion of free cash flow against $9.79 billion of dividends, a thin 89%. Pfizer has paid $0.43 a quarter all through 2026, the same rate as in fiscal 2025. CEO Albert Bourla told analysts on the second-quarter call in August, “We feel extremely confident that we will — even the most stretched scenarios that we are running, we will be able to maintain our dividend.”

So for now, I wouldn’t count on raises. Pfizer’s main risk is losing exclusivity on drugs including Ibrance, Xtandi and, outside the US, Eliquis.

Kenvue adds $1.44 billion to Kimberly-Clark’s dividend bill

Kimberly-Clark has the longer record: it says it has raised its dividend in each of the past 54 years, and it now pays $1.28 a quarter, or $5.12 a year, up from $5.04 a share in fiscal 2025.

Its third quarter was soft on sales. Net sales fell 0.4% from a year earlier to $4.1 billion, and organic sales fell 1.3%. Adjusted EPS from continuing operations still rose 17.2% to $1.70, ahead of the $1.65 analysts expected.

Free cash flow has ranged from $1.53 billion in fiscal 2019 to $2.78 billion in fiscal 2023. Over the same stretch, the dividend bill rose every year, from $1.31 billion in fiscal 2016 to $1.66 billion in fiscal 2025:

Bar chart from TIKR of Kimberly-Clark's free cash flow vs. common dividends paid, $ billions, fiscal 2016–2025.
Kimberly-Clark (KMB): free cash flow vs. common dividends paid, $ billions, fiscal 2016–2025 (TIKR)

Over the twelve months to Sept. 30, 2026, it paid $1.69 billion of dividends out of $1.94 billion of free cash flow, a tight 87%.

That ratio comes from before Kenvue. The deal brought about 281.1 million new Kimberly-Clark shares. At $5.12 a share, those add about $1.44 billion a year to the dividend bill. Management is aiming for about 2x leverage by the end of the deal’s second year. It also expects mid-single-digit dilution to 2027 EPS compared with Kimberly-Clark on its own.

So which dividend wins?

Pfizer is the better high-yield dividend stock. Its dividend is covered about as well as Kimberly-Clark’s, at 89% of free cash flow against 87%, and it pays much more. $10,000 in Pfizer pays $600 a year today, against $461 in Kimberly-Clark. At each company’s dividend growth rate from fiscal 2020 to fiscal 2025, Kimberly-Clark’s income wouldn’t pass Pfizer’s for more than 30 years. Pfizer is also cheaper, at 10x forward earnings against 16x.

Its earnings will shrink, though. Analysts expect normalized EPS to fall from $3.22 in fiscal 2025 to $2.45 in 2028:

Bar chart from TIKR of Pfizer's normalized EPS, actual and consensus estimates, $ per share, fiscal 2023-2028.
Pfizer (PFE): normalized EPS, actual and consensus estimates, $ per share, fiscal 2023-2028 (TIKR)

Their $3.04 for 2026 sits inside the $2.95 to $3.05 Pfizer now guides for, so these estimates already reflect the November report.

This isn’t to say Kimberly-Clark’s dividend is in trouble. It grew faster over the last five years. Kenvue also brings $2.1 billion of expected run-rate synergies, and if those land, the bigger bill could be easy to carry. It’s just that, for income today, I’d rather own the bigger check whose cost is already covered, while Kimberly-Clark proves Kenvue can pay its way.

Pfizer’s 2027 guidance could change that, since CFO Cecile Guegan said that guidance will reflect two of Pfizer’s drugs entering Medicare’s negotiated prices under the IRA in 2027.

Forget Pfizer: 6 safe 6%+ dividend yields you can buy right now

Dividends can hold the key to enormous wealth. But only if you buy the right ones.

Picking the right high-yield dividend stock can be the difference between a dream retirement…and scraping by every month, waiting for the next Social Security check to clear.

We’ve identified six stocks yielding 6%+ that we believe every retiree should know about right now. (And Pfizer isn’t one of them.)

Learn more here.

Disclaimer:

Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!

Join thousands of investors worldwide who use TIKR to supercharge their investment analysis.

Sign Up for FREENo credit card required